Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib

被引：42

作者：

Aarup, Kathrine ^{[1
]}

Rotbain, Emelie Curovic ^{[1
,2
]}

Enggaard, Lisbeth ^{[3
]}

Pedersen, Robert Schou ^{[4
]}

Bergmann, Olav Jonas ^{[5
]}

Thomsen, Rasmus Heje ^{[6
]}

Frederiksen, Mikael ^{[7
]}

Frederiksen, Henrik ^{[2
]}

Nielsen, Tine ^{[2
]}

Christiansen, Ilse ^{[8
]}

Andersen, Michael Asger ^{[1
]}

Niemann, Carsten Utoft ^{[1
]}

机构：

[1] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, L-4041,Blegdamsvej 9, DK-2100 Copenhagen, Denmark

[2] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[3] Herlev & Gentofte Hosp, Dept Hematol, Herlev, Denmark

[4] Hosp Senheden Vest, Dept Hematol, Holstebro, Denmark

[5] Sygehus Lillebaelt, Dept Hematol, Vejle, Denmark

[6] Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark

[7] Sygehus Snderjylland, Dept Hematol, Aabenraa, Denmark

[8] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2020年 / 105卷 / 05期

基金：

新加坡国家研究基金会;

关键词：

chronic lymphocytic leukemia; epidemiology; targeted therapy; SURVIVAL; BTK;

D O I：

10.1111/ejh.13499

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results In total, 205 patients were included of whom 39 (19%) were treatment-naive. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade >= 3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.

引用

页码：646 / 654

页数：9

共 26 条

[1]

[Anonymous], 2019, COMMON TERMINOLOGY C

[2] Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL [J].

Brown, J. R. ;

Hillmen, P. ;

O'Brien, S. ;

Barrientos, J. C. ;

Reddy, N. M. ;

Coutre, S. E. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Delgado, J. ;

Montillo, M. ;

DeVos, S. ;

Moreno, C. ;

Pagel, J. M. ;

Munir, T. ;

Burger, J. A. ;

Chung, D. ;

Lin, J. ;

Gau, L. ;

Chang, B. ;

Cole, G. ;

Hsu, E. ;

James, D. F. ;

Byrd, J. C. .

LEUKEMIA, 2018, 32 (01) :83-91

[3] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[4] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study [J].

Burger, Jan A. ;

Barr, Paul M. ;

Robak, Tadeusz ;

Owen, Carolyn ;

Ghia, Paolo ;

Tedeschi, Alessandra ;

Bairey, Osnat ;

Hillmen, Peter ;

Coutre, Steven E. ;

Devereux, Stephen ;

Grosicki, Sebastian ;

McCarthy, Helen ;

Simpson, David ;

Offner, Fritz ;

Moreno, Carol ;

Dai, Sandra ;

Lal, Indu ;

Dean, James P. ;

Kipps, Thomas J. .

LEUKEMIA, 2020, 34 (03) :787-798

[5] Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy [J].

Burger, Jan A. ;

O'Brien, Susan .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) :510-527

[6] Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials [J].

Burger, Jan A. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (01) :44-49

[7] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[8] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[9]

Christiansen I, 2019, NATL RETNINGSLINJER

[10] The Danish National Chronic Lymphocytic Leukemia Registry [J].

da Cunha-Bang, Caspar ;

Geisler, Christian Hartmann ;

Enggaard, Lisbeth ;

Poulsen, Christian Bjorn ;

Brown, Peter de Nully ;

Frederiksen, Henrik ;

Bergmann, Olav Jonas ;

Pulczynski, Elisa Jacobsen ;

Pedersen, Robert Schou ;

Nielsen, Linda Hojberg ;

Christiansen, Ilse ;

Niemann, Carsten Utoft .

CLINICAL EPIDEMIOLOGY, 2016, 8 :561-565

← 1 2 3 →